Skip to main content

Table 2 Mean IADL and PSMS scores for all patients and the sub-sample who had NARTIQ scores at baseline (week 0) and after 26, 52 and 78 weeks of cholinesterase inhibitor treatment; higher scores indicate greater dependency

From: Estimated pre-morbid IQ effects on cognitive and functional outcomes in Alzheimer disease: a longitudinal study in a treated cohort

Assessment N All patients Mean Standard deviation N Patients with NARTIQ Mean Standard deviation
IADL(0) 551 15.8 6.5 294 14.7 6.2
PSMS(0) 548 7.9 3.1 292 7.5 2.9
IADL(26) 238 17.3 5.9 146 16.9 5.9
PSMS(26) 237 8.5 3.0 146 8.3 2.8
IADL(52) 75 16.5 7.2 59 16.7 7.1
PSMS(52) 74 8.1 3.5 58 8.1 3.4
IADL(78) 46 18.0 6.1 39 18.0 6.5
PSMS(78) 46 8.5 2.7 39 8.4 2.8